Advanced imaging to extend the therapeutic time window of acute ischemic stroke

Annals of Neurology

Volumn 73, Issue 1, 2013, Pages 4-9

  Fisher, Marc ^a   Albers, Gregory W ^b  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BLOOD CLOT LYSIS; BRAIN ISCHEMIA; BRAIN PERFUSION; COMPUTER ASSISTED TOMOGRAPHY; DIFFUSION WEIGHTED IMAGING; HUMAN; MAGNETIC RESONANCE ANGIOGRAPHY; MECHANICAL THROMBECTOMY; MIDDLE CEREBRAL ARTERY OCCLUSION; NEUROIMAGING; PATIENT SELECTION; PERFUSION WEIGHTED IMAGING; PRIORITY JOURNAL; RECANALIZATION; REPERFUSION; STROKE PATIENT; THROMBECTOMY; TREATMENT RESPONSE;

ANIMALS; BRAIN ISCHEMIA; DIFFUSION MAGNETIC RESONANCE IMAGING; HUMANS; PERFUSION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STROKE; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84873345548     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.23744     Document Type: Article

References (38)

1. Ringelstein EB, for the AXIS-2 study group. The AXIS-2 study: AX 200 for the treatment of acute ischemic stroke. Stroke 2012; 43: A172.
2. Davalos A, Alvarez-Sabin J, Castillo J, et al. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet 2012; 380: 349-357.
3. Khala AM, Grotta JC,. Established treatments for acute ischaemic stroke. Lancet 2007; 369: 319-330.
4. Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008; 359: 1317-1329.
5. IST-3 Collaborative Group. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomized trial. Lancet 2012; 379: 2352-2363.
6. Lees KR, Bluhmki E, von Kummer R, et al. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet 2010; 375: 1695-1703.
7. Smith WS, Sung G, Saver J, et al. Mechanical thrombectomy for acute ischemic stroke: Final results of the Multi MERCI trial. Stroke 2008; 39: 1205-1211.
8. Penumbra Pivotal Stroke Trial Investigators. The penumbra pivotal stroke trial: safety and effectiveness of a new generation of mechanical devices for clot removal in intracranial large vessel occlusive disease. Stroke 2009; 40: 2761-2768.
9. Saver JL, Jahan R, Levy EI, et al. Solitaire flow restoration device versus the MERCI Retriever in patients with acute ischaemic stroke (SWIFT): a randomised, parallel-group, non-inferiority trial. Lancet 2012; 380: 1241-1249.
10. Nogueira RG, Lutsep HL, Gupta R, et al. TREVO versus MERCI retrievers for thrombectomy revascularization of large vessel occlusions in acute ischaemic stroke (TREVO2): a randomized trial. Lancet 2012; 380: 1231-1240.
11. Mazighi M, Serfaty JM, Labreche J, et al. Comparison of intravenous alteplase with a combined intravenous-endovascular approach in patients with stroke and confirmed arterial occlusion (RECANALISE study): a prospective cohort. Lancet Neurol 2009; 8: 802-809.
12. Jovin TG, Liebeskind DS, Gupta RA, et al. Imaging-based endovascular therapy for acute ischemic stroke due to proximal intracranial anterior circulation occlusion treated beyond 8 hours from time last seen well: retrospective multicenter analysis of 237 consecutive patients. Stroke 2011; 42: 2206-2211.
13. Rha JH, Saver JL,. The impact of recanalization on ischemic stroke outcome: a meta-analysis. Stroke 2007; 38: 967-973.
14. Mlynash M, Lansberg MG, De Silva DA, et al. Refining the definition of the malignant profile: insights from the DEFUSE-EPITHET pooled data set. Stroke 2011; 42: 1270-1275.
15. Donnan GA, Baron JC, Ma H, Davis SM,. Penumbral selection of patients for acute stroke therapy. Lancet Neurol 2009; 8: 261-269.
16. Fisher M,. Characterizing the target of acute stroke treatment. Stroke 1997; 28: 866-872.
17. Martini SR, Kent TA,. Hyperglycemia in acute ischemic stroke: a vascular perspective. J Cereb Blood Flow Metab 2007; 27: 435-451.
18. Muir KW, Buchan A, von Kummer R, et al. Imaging of acute stroke. Lancet Neurol 2006; 5: 755-768.
19. Chemmanam T, Campbell BC, Christensen S, et al. Ischemic diffusion lesion reversal is uncommon and rarely alters perfusion-diffusion mismatch. Neurology 2010; 75: 1040-1047.
20. Campbell BC, Purushotham A, Christensen S, et al. The infarct core is well represented by the acute diffusion lesion: sustained reversal is infrequent. J Cereb Blood Flow Metab 2012; 32: 50-56.
21. Baird AE, Warah S,. Magnetic resonance imaging of acute stroke. J Cereb Blood Flow Metab 1998; 18: 583-609.
22. Dani KA, Thomas RG, Chappell FM, et al. Computed tomography and magnetic resonance perfusion imaging in ischemic stroke: definitions and thresholds. Ann Neurol 2011; 70: 384-401.
23. Olivot J-M, Mlynash M, Thijs VN, et al. Optimal Tmax threshold for predicting penumbral tissue in acute stroke. Stroke 2009; 40: 469-475.
24. Zaro-Weber O, Moeller-Hartmann W, Heiss W-D, Sobesky J,. Maps of maximum and time to peak for mismatch definition in clinical stroke studies validated with positron emission tomography. Stroke 2010; 41: 2817-2821.
25. Lansberg MG, Lee J, Christensen S, et al. RAPID automated patient selection for reperfusion therapy: a pooled analysis of the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET) and the Diffusion and Perfusion Imaging Evaluation for Understanding Stroke Evolution (DEFUSE) Study. Stroke 2011; 42: 1608-1614.
26. Straka M, Albers GW, Bammer R,. Real-time diffusion-perfusion mismatch analysis in acute stroke. J Magn Reson Imaging 2010; 32: 1024-1037.
27. Lansberg MG, Straka M, Kemp S, et al. MRI profile and response to endovascular reperfusion after stroke (DEFUSE 2): a prospective cohort study. Lancet Neurol 2012; 11: 860-867.
28. Albers GW, Mylnash M, Hamilton S, et al. Benefits of endovascular reperfusion are maintained in Target Mismatch patients in late time windows. European Stroke Conference abstract e-book. Basel, Switzerland: Karger, 2012:80.
29. Mylnash M, Lansberg M, Straka, M, et al. The Malignant MRI profile: implications for endovascular therapy. Stroke 2012; 43: A53.
30. von Kummer R, Albers GW, Mori E, on behalf of the DIAS Steering Committee. The desmoteplase in acute ischemic stroke (DIAS) clinical trial programme. Int J Stroke (in press).
31. Fiebach JB, Al-Rawi Y, Wintermark M, et al. Vascular occlusion enables selecting acute ischemic stroke patients for treatment with desmoteplase. Stroke 2012; 43: 1561-1566.
32. Lansberg MG, Thijs VN, Bammer R, et al. The MRA-DWI mismatch identifies patients with stroke who are likely to benefit from reperfusion. Stroke 2008; 39: 2491-2496.
33. De Silva DA, Churilov L, Olivot JM, et al. Greater effect of stroke thrombolysis in the presence of arterial obstruction. Ann Neurol 2011; 70: 601-605.
34. Ma H, Parsons MW, Christensen S, et al on behalf of the EXTEND investigators. Extend A multicentre, randomized, double-blinded, placebo-controlled phase III study to investigate EXtending the time for Thrombolysis in Emergency Neurological Deficits (EXTEND). Int J Stroke 2012; 7: 74-80.
35. MR WITNESS. Available at: http://clinicaltrials.gov/ct2/show/NCT01282242? term=MR+WITNESS
36. Inoue M, Mlynash M, Straka M, et al. Patients with the Malignant Profile within 3 hours of symptom onset have very poor outcomes following IV tPA therapy. Stroke 2012; 43: 2494-2496.
37. Parsons M, Spratt N, Bivard A, et al. A randomized trial of tenecteplase versus alteplase for acute ischemic stroke. N Engl J Med 2012; 366: 1099-1107.
38. US National Institutes of Health Website, MR and recanalization of stroke clots using embolectomy (MR RESCUE) trial. Available at: clinicaltrials.gov/ct/ show/NCT01282242. Accessed July 24, 2012.